Instil Bio, Inc. (TIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
TIL Stock Price Chart Interactive Chart >
TIL Price/Volume Stats
|Current price||$0.82||52-week high||$13.01|
|Prev. close||$0.78||52-week low||$0.47|
|Day high||$0.85||Avg. volume||1,528,894|
|50-day MA||$0.94||Dividend yield||N/A|
|200-day MA||$4.51||Market Cap||105.90M|
Instil Bio, Inc. (TIL) Company Bio
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Most Popular Stories View All
TIL Latest News Stream
|Loading, please wait...|
TIL Latest Social Stream
View Full TIL Social Stream
Latest TIL News From Around the Web
Below are the latest news stories about INSTIL BIO INC that investors may wish to consider to help them evaluate TIL as an investment opportunity.
Instil Bio, Inc., belongs to Healthcare sector and Biotechnology industry. The company’s Market capitalization is $95.33MB with the total Outstanding Shares of 129.68M. TIL Stocks -33.91% Far from 50 Day Moving Average After a … The post Current Momentum Stock: Instil Bio, Inc. (NASDAQ:TIL) (Gain, ↑) appeared first on Stocks Equity .
Instil Bio Inc. (NASDAQ: TIL) Jumps 5.73% In Recent Session, What Are The Points You Absolutely Need To Consider?
Instil Bio Inc. (NASDAQ:TIL) price closed higher on Monday, January 09, jumping 5.73% above its previous close. A look at the daily price movement shows that the last close reads $0.63, with intraday deals fluctuated between $0.6401 and $0.7421. Taking into account the 52-week price action we note that the stock hit a 52-week high … Instil Bio Inc. (NASDAQ: TIL) Jumps 5.73% In Recent Session, What Are The Points You Absolutely Need To Consider? Read More »
Instil Bio Inc (NASDAQ: TIL) has resumed its Phase 1 clinical trial of ITIL-306 for non-small cell lung cancer (NSCLC), ovarian cancer, and renal cell carcinoma (RCC). With the resumption of the ITIL-306 Phase 1 study, the company plans to release initial safety, translational, and efficacy data from dose escalation cohorts at a medical conference in 2023. The trial was resumed after implementing additional quality safeguards designed to further protect the manufacturing process from potential c
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause Initial data readout for ITIL-306 expected in 2023 With recent reprioritization of clinical programs and corporate restructuring, company expects cash runway into 2025, excluding potential financing or other monetization of Tarzana manufacturing site DALLAS, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focus
Instil Bio Inc. (NASDAQ:TIL) traded at $0.60 at close of the session on Tuesday, 01/03/23, made a downward move of -4.76% on its previous day’s price. Looking at the stock we see that its previous close was $0.63 with the day’s price range being $0.5901 – $0.66. In terms of its 52-week price range, TIL … Instil Bio Inc. (NASDAQ: TIL) Has Been Trading Down. What Are The Prospects For The Future? Read More »
TIL Price Returns